Modified analogs were shown to downregulate BCR-ABL more efficiently than the parent compound, with increased ability to trigger apoptosis in imatinib-resistant CML models [114]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.